Close Menu

Breaking News

Inhibiting the associated protein, PAI-1, appeared to ease inflammation and symptoms in a mouse model of inflammatory bowel disease.

With the acquisition of Swiss healthcare AI specialist SimplicityBio, Precision for Medicine can offer new features in its QuartzBio multiomic data integration platform.

The companies will develop an IVD system based on the MiniSeq initially to diagnose hereditary kidney disease.

The company plans to sell 9 million shares at $19.00 per share, which is expected to bring in $171.0 million in gross proceeds.

The company said it will use part of the proceeds to repurchase some of its senior notes due in January 2025, and the rest for corporate purposes.

Last year, the Gottlieb-led FDA approved 25 new molecularly-defined drugs and expanded indications compared to 19 in the prior year, and issued a slew of guidelines important for the personalized medicine field. 

The license contains a new method and bioinformatic tools that improve detection in next-generation sequencing to help researchers identify rare gene variants.

A genome-wide association study involving more than 12,300 carpal tunnel syndrome patients and controls from the UK Biobank led to 16 genetic loci.

A team led by researchers at the University of California, San Francisco generated optical genome maps for 154 individuals from more than two dozen populations.

The test is designed to determine which early-stage, estrogen receptor-positive breast cancer patients are likely to benefit from extended endocrine therapy.

Invitae hasn't priced the offering yet or disclosed how many shares it will offer, but it expects net proceeds to range from $117.1 million to $134.7 million.

The ctDNA test will be covered for all US fee-for-service Medicare patients with advanced (Stage IIIB/IV) NSCLC who meet specific clinical criteria.

University of Bristol researchers unearthed variants that implicate the immune system in the risk of developing mouth ulcers.

The funds will be used to finalize a cloud-based version of the company's ImmnoGenomiX platform slated for release next month.

In a different study, investigators found that adenine base editors and cytosine base editors recognize different off-target sites.

Geisinger will use the funding to develop genomic-based approaches for detecting arrhythmogenic right ventricular cardiomyopathy to aid in early intervention.

In an SEC document, the company said net proceeds are expected to be $5.8 million and will be used to support an anticipated submission to the FDA, among other things.

Starting with samples from an 11-year-old boy with spitzoid melanoma, researchers identified recurrent MAP3K8 fusions that may respond to MEK inhibitors.

The LCD will enable coverage of Envisia in patients for whom imaging does not lead to a definitive diagnosis of idiopathic pulmonary fibrosis.

Taiwanese startup Atgenomix and Yourgene Bioscience Taiwan are combining technologies to build a "comprehensive" system for WGS and WES variant analysis.

Last week, GenomeWeb's readers were most interested in Danaher's acquisition of General Electric's Biopharma business for $21.4 billion in cash.

The PhosphorusOne test uses next-generation sequencing to analyze 375 genes covering 170 inherited conditions and 175 different drug reactions.

The index — which outperformed the Dow Jones, the Nasdaq, and the Biotechnology Index this month — gained more than 8 percent.

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.